Omega Therapeutics Inc
NASDAQ:OMGA

Watchlist Manager
Omega Therapeutics Inc Logo
Omega Therapeutics Inc
NASDAQ:OMGA
Watchlist
Price: 0.0485 USD 7.78% Market Closed
Market Cap: $2.7m

Operating Margin

-916%
Current
Improving
by 2 231.1%
vs 3-y average of -3 147.1%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-916%
=
Operating Income
$-74.2m
/
Revenue
$8.1m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-916%
=
Operating Income
$-74.2m
/
Revenue
$8.1m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Omega Therapeutics Inc
NASDAQ:OMGA
2.7m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

Lower than 93% of companies in the United States of America
Percentile
7th
Based on 14 112 companies
7th percentile
-916%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Omega Therapeutics Inc
Glance View

Market Cap
2.7m USD
Industry
Biotechnology

Omega Therapeutics, Inc. engages in the development of DNA-sequence-targeting, mRNA-encoded therapeutics. The company is headquartered in Cambridge, Massachusetts. The company went IPO on 2021-07-30. The firm is engaged in a systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming platform. Its OMEGA Epigenomic Programming platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism's life from cell genesis, growth, and differentiation to cell death. The company has deciphered the three-dimensional architecture of the human genome and its accompanying regulators, which are organized into distinct and evolutionarily conserved structures called Insulated Genomic Domains (IGDs). The OMEGA platform enables to systematically identify and validate thousands of DNA-sequence-based epigenomic zip codes within IGDs. Its pipeline consists of early-stage, preclinical programs that span regenerative medicine, multigenic diseases including immunology, oncology, and select monogenic diseases.

OMGA Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-916%
=
Operating Income
$-74.2m
/
Revenue
$8.1m
What is Omega Therapeutics Inc's current Operating Margin?

The current Operating Margin for Omega Therapeutics Inc is -916%, which is above its 3-year median of -3 147.1%.

How has Operating Margin changed over time?

Over the last 3 years, Omega Therapeutics Inc’s Operating Margin has increased from -27 111.1% to -916%. During this period, it reached a low of -27 111.1% on Mar 31, 2022 and a high of -916% on Oct 30, 2024.

Back to Top